Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Current opinions in nephrology and hypertension

kidney transplantation in patients with plasma cell dyscrasias

Lum, Erik L.; Bunnapradist, Suphamai

Current Opinion in Nephrology and Hypertension: November 2019 - Volume 28 - Issue 6 - p 573–580
doi: 10.1097/MNH.0000000000000544
DIALYSIS AND TRANSPLANTATION: Edited by Anil Chandraker and J. Kevin Tucker

Purpose of review Plasma cell dyscrasias encompass a group of hematological disorders characterized by increased production of immunoglobulins by clonal B cells. Kidney involvement is common. Significant advances in the treatment of plasma cell dyscrasias have resulted in improved survival and may permit kidney transplantation in candidates previously denied transplantation. Treatments may also have effects on kidney transplant recipients who develop plasma cell dyscrasias post transplantation.

Recent finding The available evidence suggests that transplantation of candidates with nonmultiple myeloma plasma cell dyscrasias provides good outcome with low recurrence rates, so long as the disease has been treated with a complete or good partial response prior to transplantation. Candidates with a history untreated MGRS or a history of multiple myeloma have a high rate of recurrence posttransplant. Kidney transplant recipients who develop plasma cell dyscrasias post transplantation have an increased risk of death and thalidomide-based regimens may increase the risk of rejection.

Summary Transplant candidates with a history of plasma cell dyscrasia who are in remission should not be excluded from transplantation. Individuals with multiple myeloma have a high rate of recurrence and myeloma post kidney transplant must be managed carefully.

Division of Nephrology, David Geffen School of Medicine, Los Angeles, California, USA

Correspondence to Erik L. Lum, MD, Connie Frank Kidney Transplant Center, 200 Medical Plaza, Ste 565, Los Angeles, CA 90095, USA. Tel: +1 310 267 0552; e-mail:

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.